Tag: PHARMACEEUTICALS

Global pharmaceutical giant Pfizer has announced a major partnership with Chinese biotech firm 3SBio Inc. to develop and market a promising new cancer drug. The agreement marks a significant step in international collaboration on cancer treatment innovation. Under the deal, Pfizer will license the experimental therapy, known as SSGJ-707, a next-generation bispecific antibody designed to target PD-1 and VEGF—proteins commonly linked to cancer growth. This drug is currently being tested in clinical trials across China for a range of cancers, including non-small cell lung cancer, colorectal cancer, and certain gynecological tumors. Key Details of the Deal: Pfizer will pay $1.25 billion upfront and could make additional payments totaling up to $4.8 billion if the drug meets development and sales milestones. The company will also invest $100 million in 3SBio through a strategic equity stake. Pfizer gains exclusive global rights to develop, produce, and commercialize the drug—excluding China, though it retains the option to expand there later. U.S. regulators have already approved the drug’s Investigational New Drug (IND) application, paving the way for testing in American trials. Manufacturing is expected to take place in North Carolina (drug substance) and Kansas (final product). Why It Matters: This collaboration is a bold move by Pfizer to grow its oncology pipeline and signals increasing confidence in the innovation coming out of China’s biotech sector. With a Phase III trial on the horizon, SSGJ-707 could become a global player in the fight against cancer. Following the announcement, 3SBio’s stock soared by 35% on the Hong Kong exchange, boosting its market value to nearly $6 billion.